Roche Secures First U.S. Approval for New Breast-Cancer Pill

By Adria Calatayud

 

Roche Holding received the green light from the U.S. Food and Drug Administration to launch a new pill to treat advanced breast cancer, the first approval for what executives say could become the company's top-selling product.

The Swiss drugmaker said late Monday that the medicine--marketed under the Wilserdly brand and also known as giredestrant--was approved in combination with Novartis's Afinitor for the treatment of a type of advanced or metastatic breast cancer. The company is also awaiting a decision from the FDA on the potential approval for the same drug at an earlier phase of the disease, which would make it available to a bigger group of patients.

Roche has said the drug has potential to redefine how breast cancer is treated. But it is due to face competition from new products AstraZeneca and Eli Lilly are developing, as well as existing treatments already on the market.

The first FDA approval for Wilserdly marks a milestone in Roche's breast-cancer franchise that strengthens the company's growth outlook, and it could be followed by a larger opportunity in early-stage disease, Swiss private bank Vontobel wrote in a note to clients.

Wilserdly is a so-called selective estrogen receptor degrader designed to stop or slow down the growth of cancer cells by breaking down the estrogen-receptor protein they use as fuel to spread.

AstraZeneca in September received FDA approval for a medicine that belongs to the same class, Etcamah, for advanced breast cancer upon detection of a resistance mutation, and is also conducting studies to test the drug in earlier stages of the disease.

The late-stage study that was the basis for Roche's application showed the drug significantly outperformed the standard therapy in reducing the risk of disease progression or death for patients with locally advanced or metastatic breast cancer, the company said.

"It's important to bring new and better treatment options to patients," Roche Deputy Chief Medical Officer Stefan Frings said in an interview. "Giredestrant really has set a new benchmark."

Executives at Roche previously said the medicine could become the company's top-selling product ever. The company has guided for the drug to generate more than 3 billion Swiss francs ($3.57 billion) in annual sales at its peak.

 

Write to Adria Calatayud at adria.calatayud@wsj.com

 

(END) Dow Jones Newswires

November 17, 2026 03:09 ET (08:09 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center